Royalty Pharma plc Business Acquisition, Pro Forma Net Income (Loss)
Royalty Pharma plc (RPRX) reported Business Acquisition, Pro Forma Net Income (Loss) of $1.40 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2026-08-05
- Royalty Pharma plc business acquisition, pro forma net income (loss) for the quarter ending 2025-12-31 was $356.26M, a 15.23% increase year-over-year.
- Royalty Pharma plc business acquisition, pro forma net income (loss) for the quarter ending 2025-09-30 was $445.17M, a 43.44% decline year-over-year.
- Royalty Pharma plc business acquisition, pro forma net income (loss) for the quarter ending 2025-06-30 was $132.99M, a 13.97% decline year-over-year.
- Royalty Pharma plc business acquisition, pro forma net income (loss) for the quarter ending 2024-12-31 was $309.18M.
- Royalty Pharma plc business acquisition, pro forma net income (loss) for fiscal 2025 was $1.40B, a 22.80% increase from fiscal 2024.
- Royalty Pharma plc business acquisition, pro forma net income (loss) for fiscal 2024 was $1.14B.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $356.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $801.43M derived: sum of 2 quarters · filed 2026-02-11 | $934.41M derived: sum of 3 quarters · filed 2026-08-05 | $1.40B 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $445.17M 10-Q · filed 2025-11-05 | $578.15M derived: sum of 2 quarters · filed 2026-08-05 | $1.04B 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $132.99M 10-Q · filed 2026-08-05 | $130.99M 10-Q · filed 2025-08-06 | $596.23M 10-Q · filed 2026-08-05 | $593.23M 10-Q · filed 2025-08-06 | ||
| 2024-12-31 | $309.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.10B derived: sum of 2 quarters · filed 2026-02-11 | $1.25B derived: sum of 3 quarters · filed 2026-02-11 | $1.14B 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $787.02M 10-Q · filed 2025-11-05 | $941.60M derived: sum of 2 quarters · filed 2025-11-05 | $827.44M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $154.58M 10-Q · filed 2025-08-06 | $52.31M 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |